Bradley M

Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham.

6 papers · ORCID

ArticlePsilocybin

Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT.

Simonsson O, Bradley M, Black JC +3

Europe PMC2026
ArticlePsilocybin

Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial.

Hendricks PS, Lappan SN, Shelton RC +8

Europe PMC2026
ArticlePsychedelics

How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.

Dourron HM, Copes H, Grossman DH +6

Europe PMC2025
ArticlePsychedelics

Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders.

Dourron HM, Bradley M, Simonsson O +4

Europe PMC2025
ArticleLSD

Rural-urban divide in risk perception of LSD: Implications for psychedelic-assisted therapy.

Bradley M, Grossman D, Simonsson O +2

Europe PMC2025
ArticleDMT

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Dourron HM, Nichols CD, Simonsson O +3

Europe PMC2025